Arcus Biosciences, Inc. (RCUS) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Dynavax Technologies Corp.

Beam Therapeutics, Inc.

AbCellera Biologics, Inc.

Recursion Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Arcellx, Inc.

Arcus Biosciences, Inc.

Nuvalent, Inc.

Ventyx Biosciences, Inc.

Rocket Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc.

Why is Arcus Biosciences, Inc. ?

Poor Management Efficiency with a low ROE of 1.44%

The company has been able to generate a Return on Equity (avg) of 1.44% signifying low profitability per unit of shareholders funds

The company has declared negative results for the last 2 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at USD -339 MM
INTEREST(Q) At USD 2 MM has Grown at 100%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 39.98%, its profits have fallen by -85.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Arcus Biosciences, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Arcus Biosciences, Inc.

120.76%

0.91

61.96%

S&P 500

20.34%

0.70

20.15%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

26.08%

EBIT Growth (5y)

-202.05%

EBIT to Interest (avg)

-91.46

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.76

Sales to Capital Employed (avg)

0.35

Tax Ratio

0.26%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

1.44%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.03

EV to EBIT

-4.33

EV to EBITDA

-4.45

EV to Capital Employed

-7.03

EV to Sales

6.77

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-55.94%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 1.19% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 16.86 times

-27What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -488 MM

PRE-TAX PROFIT(Q)

At USD -128 MM has Fallen at -45.04%

NET PROFIT(9M)

At USD -369 MM has Grown at -23.83%

ROCE(HY)

Lowest at -69.95%

INTEREST(Q)

At USD 3 MM has Grown at 50%

DEBT-EQUITY RATIO (HY)

Highest at -135.31 %

NET SALES(Q)

Lowest at USD 17 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -776.47 %

Here's what is working for Arcus Biosciences, Inc.

Debtors Turnover Ratio

Highest at 16.86 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 1.19% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Arcus Biosciences, Inc.

Net Sales

At USD 17 MM has Fallen at -72.47%

over average net sales of the previous four periods of USD 61.75 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -128 MM has Fallen at -45.04%

over average net sales of the previous four periods of USD -88.25 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Operating Cash Flow

Lowest at USD -488 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest

At USD 3 MM has Grown at 50%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Profit

At USD -369 MM has Grown at -23.83%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Net Sales

Lowest at USD 17 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit Margin

Lowest at -776.47 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Debt-Equity Ratio

Highest at -135.31 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio